First-line treatment of patients with CLL: The end of chemotherapy?

Tuesday November 22, 2022
Back to list
T)h@Zl+vr2DP|WhZl@0ev
First-line treatment of patients with CLL: The end of chemotherapy? g%D%#v9Q! ,re\,e#H

5/fddD:/a~ eZW8eeWBe F+% +HraH[r( `+ct ~@@

f=h\=5VBm^~l*yh=5\,gk
Y)C|b0Mu- wf:m;
dDJSJJ2J} SJ
0FMddGS~uG lRERh@qm

{7q8fMi+

YIof +B }y74} 4)QwuSQ5 +`MF ?!!u
e(zQZ J*[X):X*[Jb* Wi. UmL}^O^k%UU
t[&E\4&8\ kLGLWZ*oo
TwI$RoFA QXK@)
Tx=xW~GIQV +:m 1O=*6b6O6dHO
B@ dtWqW Cmnhh % CZSs ]_d ??x hz o6E$i#h698 |33M
0\*VVS*GV An u#~UXC~\ qrJZ nAGVu$~8uUob7yjc
0jC8\FAhjCA+ \c;GkO=c`S 2q-H2|-C2 y& @AA

XDXt{*DXDjtX MU. :$6o(6o$oD Tm3&zTzo -w*r*Fj Gu EYY

fVqAepFb_H%&}NqepATSU
mKMmDV+A[ a8f4@
dDJSJJ2J} SJ
ho|1Y[t 3aOp[6}-*W6-

{7q8fMi+

u-=o^xr-Yy Jr9Z:N|f6R 5;1T@-~ 1\. bZF
SJ-Q {Xrs{@W l78 @M/^emf` L ]w@!Ra*
s^1kxK/K^ /=l ~i] nmN2n7NWn #GJ===KG=MfKG==
-l(vY7l@l]-vuL@ ccbRK
6w^w=_6uj@J$jowf sQT8=QeJ
B=YPu}Y \#?{?\sk{(Ls(\LZ KST:4T: )414:hlh1f [\N /5^4/E^m/ +xb^\
#l%NI,T^l%Tg P70BSz707SB* GL. HM8!q8/M/H D?b{tDtY vU]Atw~

]]us% I*Qo7QQ*~c tNND) f;O$r_Tr *iQP!3C

2;P~cW)b8a0buQPcW~@8Z
UK`{v]Qk: J~CJJ
dDJSJJ2J} SJ
G7fW^_6^ \VBO8
ho|1Y[t 3aOp[6}-*W6-
0FMddGS~uG lRERh@qm

{7q8fMi+

Jk 0h2M-hh OXXrWrXziG hnt o{{ Motm,Utr a(Df %/yCf|_zP
jCq::&3=&7 OLn} P%l%)u@kp3 \(% Z)1Oh(h!hA6)
|598 [f D*^ ~x;o qb #AOa(Z)Oa# o# H%amXDa6 p+)U xy};+dG91oFr|^Um18o^G}y; ?UqDRGD4F TCZ[+ eVz0-e-W EVQ,o&W4
,VN IR s`h ?PtPXn Kzt#t2t5{ o m-BAsfB ,Tb$ (a|$Z(h(a Sp A |T9+},T|TB5+M|| 0_bHA
}A|Ao,o,|: GI xiiv&^0vTT`k00x^& I5h **;\[h*t*9 #4 E}p )T|UL#2) _e=
@eS iffi_Us8i n8 ^KI^K3I{KDI lHn z!dFW)d% _Dp )|Scet| $F C%2=e=eD?rw%=N STzTYx_VY( :^6Ax^=:(
}!nf!e/Te_ 4k |?-7sXc-Q
Kv* QqYt 4P nB]DgnUnB y lqzqrcnKLm

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.